Carnegie Capital Asset Management LLC lifted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 19.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 123,114 shares of the biopharmaceutical company’s stock after buying an additional 20,400 shares during the quarter. Carnegie Capital Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $7,379,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. W.G. Shaheen & Associates DBA Whitney & Co purchased a new stake in shares of Bristol-Myers Squibb in the first quarter worth about $101,000. Institutional & Family Asset Management LLC purchased a new stake in shares of Bristol-Myers Squibb in the first quarter worth about $106,000. Centerpoint Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 373.1% in the first quarter. Centerpoint Advisors LLC now owns 1,774 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,399 shares during the last quarter. CSat Investment Advisory L.P. purchased a new stake in shares of Bristol-Myers Squibb in the second quarter worth about $113,000. Finally, Landaas & Co. WI ADV purchased a new stake in shares of Bristol-Myers Squibb in the second quarter worth about $131,000. Hedge funds and other institutional investors own 72.24% of the company’s stock.

A number of equities analysts have issued reports on the company. SunTrust Banks reiterated a “buy” rating and set a $67.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, July 31st. BMO Capital Markets reiterated a “hold” rating on shares of Bristol-Myers Squibb in a research report on Sunday, July 22nd. Jefferies Financial Group set a $58.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Sunday, July 15th. ValuEngine upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, July 14th. Finally, Credit Suisse Group reiterated a “hold” rating and set a $61.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, September 12th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $62.89.

Shares of Bristol-Myers Squibb stock opened at $61.30 on Tuesday. Bristol-Myers Squibb Co has a 12 month low of $49.96 and a 12 month high of $70.05. The company has a market cap of $99.20 billion, a price-to-earnings ratio of 20.37, a PEG ratio of 1.53 and a beta of 1.02. The company has a quick ratio of 1.28, a current ratio of 1.40 and a debt-to-equity ratio of 0.46.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $0.14. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. The business had revenue of $5.70 billion during the quarter, compared to analysts’ expectations of $5.48 billion. During the same quarter in the prior year, the firm earned $0.74 earnings per share. The business’s revenue was up 10.9% compared to the same quarter last year. equities research analysts anticipate that Bristol-Myers Squibb Co will post 3.62 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, November 1st. Shareholders of record on Friday, October 5th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, October 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.61%. Bristol-Myers Squibb’s payout ratio is currently 53.16%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Article: What is the Dow Jones Industrial Average (DJIA)?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.